Background: Oesophageal squamous cell carcinoma (ESCC) remains a highly aggressive malignancy with limited biomarkers for monitoring tumour burden and prognosis. Circulating tumour DNA (ctDNA) has emerged as a promising tool for real-time disease assessment, but its clinical utility in ESCC remains underexplored.
Methods: In this prospective cohort study, we analysed preoperative and postoperative ctDNA from 54 treatment-naïve ESCC patients undergoing radical surgery using a 61-gene panel. Associations between ctDNA mutations, clinicopathological characteristics and survival outcomes were evaluated.
Results: Preoperative ctDNA mutations were detected in 96.3% of patients (52/54), with Tumour Protein 53 (TP53) (59.3%), Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) (31.5%) and Phosphatase and Tensin Homologue (PTEN) (13.0%) being most prevalent. Surgical resection significantly reduced ctDNA positivity (p < .0001). Advanced-stage tumours exhibited higher frequencies of PIK3CA (47.8% vs. 19.4%, p = .026) and PTEN mutations (26.1% vs. 3.2%, p = .034). Survival analysis revealed that postoperative TP53 ctDNA positivity predicted worse disease-free survival (DFS; Hazard Ratio (HR) = 3.64, p = .005) and overall survival (OS; HR = 3.29, p = .009), while PIK3CA positivity was associated with improved OS (p = .032). Strikingly, preoperative PTEN ctDNA-positive patients showed dramatically worse outcomes, with median DFS of 4.01 versus 33.27 months (HR = 7.53, p < .001) and OS of 11.80 versus 45.17 months (HR = 5.35, p < .001). In multivariate analysis, preoperative PTEN positivity remained the strongest independent prognostic factor for both DFS (HR = 7.28, p = .002) and OS (HR = 3.76, p = .028), surpassing Tumour, Node, Metastasis (TNM) stage.
Conclusions: Our findings highlight the dynamic role of ctDNA in reflecting ESCC tumour burden and prognosis. While tumour-agnostic ctDNA analysis showed limited clinical utility, gene-specific mutations (TP53, PIK3CA and PTEN) demonstrated significant prognostic value. Preoperative PTEN ctDNA positivity emerged as a robust predictor of aggressive disease, suggesting its potential for risk stratification and personalised therapeutic strategies in ESCC.
| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.
|
| [2] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2): 115-132.
|
| [3] |
Low DE, Kuppusamy MK, Alderson D, et al. Benchmarking complications associated with esophagectomy. Ann Surg. 2019; 269(2): 291-298.
|
| [4] |
van Erning FN, Nieuwenhuijzen GAP, van Laarhoven HWM, et al. Gastrointestinal symptoms after resection of esophagogastric cancer: a longitudinal study on their incidence and impact on patient-reported outcomes. Ann Surg Oncol. 2023; 30(13): 8203-8215.
|
| [5] |
Van der Wilk BJ, Eyck BM, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge cluster randomised trial. Paper presented at: Congress of the European-Society-for-Medical-Oncology (ESMO); October 20–24, 2023; Madrid, Spain.
|
| [6] |
Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019; 18(1): 114.
|
| [7] |
Egyud M, Tejani M, Pennathur A, et al. Detection of circulating tumor DNA in plasma: a potential biomarker for esophageal adenocarcinoma. Ann Thorac Surg. 2019; 108(2): 343-349.
|
| [8] |
Azad TD, Chaudhuri AA, Fang P, et al. Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology. 2020; 158(3): 494-505.
|
| [9] |
Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014; 4(6): 650-661.
|
| [10] |
Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease—latest advances and implications for cure. Nat Rev Clin Oncol. 2019; 16(7): 409-424.
|
| [11] |
Chen X, Gole J, Gore A, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun. 2020; 11(1): 3475.
|
| [12] |
Abbosh C, Birkbak NJ, Wilson GA, et al. Corrigendum: phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2018; 554(7691): 264.
|
| [13] |
Duffy MJ, McDermott EW, Crown J. Blood-based biomarkers in breast cancer: from proteins to circulating tumor cells to circulating tumor DNA. Tumour Biol. 2018; 40(5): 1010428318776169.
|
| [14] |
Wang Y, Yang L, Bao H, et al. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: a prospective cohort study. PLoS Med. 2021; 18(8): e1003741.
|
| [15] |
Hao JJ, Lin DC, Dinh HQ, et al. Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. Nat Genet. 2016; 48(12): 1500-1507.
|
| [16] |
Chen K, Yang F, Shen H, et al. Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer. Cancer Cell. 2023; 41(10): 1749-1762.e6.
|
| [17] |
Moding EJ, Nabet BY, Alizadeh AA, Diehn M, Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov. 2021; 11(12): 2968-2986.
|
| [18] |
Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution [published correction appears in Nature. 2018;554(7691):264]. Nature. 2017; 545(7655): 446-451.
|
| [19] |
Abbosh C, Frankell AM, Harrison T, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023; 616(7957): 553-562.
|
| [20] |
Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015; 7(302): 302ra133.
|
| [21] |
Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016; 8(346): 346ra92.
|
| [22] |
Nakai M, Yamada T, Sekiya K, et al. Use of liquid biopsy to detect PIK3CA mutation in metastatic breast cancer. J Nippon Med Sch. 2022; 89(1): 66-71.
|
| [23] |
Thao DT, Thanh NP, Quyen DV, Khai LT, Song LH, Trung NT. Identification of breast cancer-associated PIK3CA H1047R mutation in blood circulation using an asymmetric PCR assay. PLoS One. 2024; 19(8): e0309209.
|
| [24] |
Yining W, Qiaochu C, Liangrong W, Cheng W, Jianjun L. Correlation between PTEN/TP53 expression and molecular imaging phenotypes in primary prostate cancer. Chin J Nucl Med Mol Imaging. 2025; 45(05): 257-262.
|
| [25] |
Zhang L, Sun S, Zhao X, et al. Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer. Mol Oncol. 2022; 16(20): 3689-3702.
|
| [26] |
Hou J, Jiang D, Zhang J, et al. Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma. Hum Pathol. 2014; 45(2): 352-358.
|
| [27] |
Pang H, Flinn R, Patsialou A, et al. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res. 2009; 69(23): 8868-8876.
|
| [28] |
Yates LR, Knappskog S, Wedge D, et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell. 2017; 32(2): 169-184.e7.
|
| [29] |
Fillbrunn M, Signorovitch J, André F, et al. PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials. BMC Cancer. 2022; 22(1): 1002.
|
| [30] |
Li S, Shen Y, Wang M, et al. Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis. Oncotarget. 2017; 8(19): 32043-32054.
|
| [31] |
Cohen SA, Kasi PM, Aushev VN, et al. Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer. J Clin Oncol. 2023; 41(4 suppl) ASCO GI 2023 abstr 5.
|
| [32] |
Tu CC, Hsu PK, Chien LI, et al. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery. BMC Cancer. 2017; 17(1): 62.
|
RIGHTS & PERMISSIONS
2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
PDF
